No abstract

The purpose of this study is to evaluate tumor control and failure patterns in patients with low grade gliomas treated with surgery and conventional adjuvant radiation therapy. Twenty-eight patients with low grade gliomas (7 grade I, 21 grade II) were retrospectively evaluated. Extent of resection was gross total (3), subtotal (17), and biopsy alone (8). All grade I tumors underwent subtotal resection. Median radiation therapy dose was 54 Gy delivered to localized fields. Tumor control and patterns of failure were determined from follow-up computed tomography and/or magnetic resonance scans. Median follow-up was 86 months (range, 2.4-177 months). Thirteen patients (46%) (four grade I, nine grade II) developed tumor progression. The 5-year actuarial progression-free survival rates for grade I and grade II patients were 86% and 51%, respectively. Corresponding 5-year actuarial survival rates were 100% and 70%. All recurrences were within the treated volume. Our results reveal that conventional adjuvant radiation therapy is associated with high rates of local tumor progression in both grade II and incompletely resected grade I low grade gliomas. Alternative strategies need to be explored in these patients in an effort to improve tumor control and outcome.

No abstract

Immunization of mice with phosphorylcholine (PC)-bearing Staphylococcus pneumoniae Type 2, strain 36a (R36a) results in both a PC-specific and a polyclonal increase in splenic plaque-forming cells. The polyclonal increase was observed in all strains tested, including those bearing an X-linked immune defect resulting in an undetectable anti-PC immune response. The magnitude of the polyclonal response is directly related to the amount of bacterial surface PC as detected by enzyme-linked immunosorbent assay. Congenitally athymic (nude) mice mount an anti-PC plaque-forming cell response after R36a immunization but fail to produce a significant polyclonal response. From our results it appears that PC on the cell wall of a bacterium acts both as a polyclonal activator and a specific antigen, stimulating each by different mechanisms.

No abstract